Verily joins with Janssen, adding Covid-19 to Project Baseline study
Verily and Janssen say studying Covid-19 immune responses could yield data that helps clinicians treat the disease. They add that the research could also apply to other illnesses caused by respiratory pathogens.
Shares0
When Verily unveiled $700 million in funding late last year, it said the cash would support its Covid-19 research. Some of those research plans are now taking shape.
Verily, the life sciences division of Google parent company Alphabet, is adding Covid-19 to Project Baseline, an expansive study collecting health data from thousands of patient volunteers and following them over time to create a comprehensive map of human health. The patient information contributes to a database that could offer insight into the biological drivers of health and illness.
What You Should Know:
– Verily and Janssen launches COVID-19 Immune Response Study that aims to collect detailed information about how the coronavirus affects the immune system immediately after someone tests positive for COVID-19.
Verily, an Alphabet company, is partnering with Janssen Research & Development LLC (Janssen) to launch a COVID-19 Immune Response Study as part of Verily’s Project Baseline. The study aims to collect detailed information about how the coronavirus affects the immune system immediately after someone tests positive for COVID-19. Project Baseline is an initiative to make it easy and engaging for people to contribute to the map of human health and participate in clinical research.